TABLE 3.
FAs | BSA | EPA | DHA |
14:0 | 0.6 ± 0.6 | 0.3 ± 0.3 | 0.2 ± 0.3 |
16:0 | 17.6 ± 5.4 | 11.0 ± 3.6 | 13.2 ± 3.1 |
16:1 | 2.1 ± 1.0 | 1.3 ± 0.6 | 1.4 ± 0.5 |
18:0 | 18.1 ± 1.0 | 9.6 ± 0.6*** | 10.8 ± 0.6*** |
cis 18:1 | 26.2 ± 1.2 | 13.8 ± 0.3*** | 16.3 ± 0.3*** |
18:2(n–6) | 3.5 ± 0.1 | 2.3 ± 0.1*** | 2.6 ± 0.1*** |
20:4(n–6) | 16.4 ± 2.0 | 7.3 ± 0.7** | 8.6 ± 0.4** |
20:5(n–3) | 0.9 ± 0.1 | 38.6 ± 3.5*** | 0.9 ± 0.1 |
22:5(n–3) | 6.8 ± 1.1 | 13.0 ± 1.1* | 3.2 ± 0.3 |
22:6(n–3) | 7.8 ± 2.1 | 2.7 ± 0.4 | 42.7 ± 2.5*** |
∑ SFAs | 40.3 ± 5.7 | 21.0 ± 3.9* | 26.8 ± 3.0 |
∑ MUFAs | 28.0 ± 0.2 | 15.1 ± 0.5* | 17.9 ± 0.3* |
∑ (n–3) PUFAs | 13.9 ± 3.7 | 54.3 ± 3.9*** | 44.4 ± 2.9** |
∑ (n–6) PUFAs | 17.8 ± 1.8 | 9.6 ± 0.7*** | 10.1 ± 0.4* |
B cells were treated with BSA or 25 μmol EPA or DHA/L for 24 h. Data are means ± SEMs from 5 independent experiments. Values (arbitrary units) are percentage of total FAs. Asterisks indicate statistical significance relative to the BSA control: *P < 0.05, **P < 0.01, ***P < 0.001.